Clinical Trial Results:
            A phase II multi-center, open-label, study of Nilotinib at a dose of 300mg twice daily in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
    
|     Summary | |
|     EudraCT number | 2008-004551-30 | 
|     Trial protocol | IE GB DE | 
|     Global completion date | |
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | |
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | |
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | |
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    12 Mar 2025
                             | 
|     First version publication date | 
                                    12 Mar 2025
                             | 
|     Other versions | |
|     Summary report(s) | 2008-004551-30 results posted 24Feb25 | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
